Description: XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Home Page: www.xtlbio.com
5 Badner Street
Ramat Gan,
5218102
Israel
Phone:
972 3 611 6600
Officers
| Name | Title |
|---|---|
| Mr. Shlomo Spokone Shalev | CEO & Director |
| Mr. Itay Weinstein | Chief Financial Officer |
| Mr. Ronen Kantor | Company Sec. |
Exchange: TA
Country: IL
Currency: Israeli Agora (ILA)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |